-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
GlaxoSmithKline (GSK) and Medicago recently announced that the COVID-19 plant-derived vaccine candidate added with GSK pandemic adjuvant has achieved positive results in its efficacy and safety in the global phase 3 placebo-controlled efficacy study
The vaccine's efficacy has been proven in an environment dominated by SARS-CoV-2 variants, which is different from most of the published Phase 3 trials
During the study period, no related serious adverse events were reported, and the reactogenicity was generally mild to moderate and transient; the symptoms lasted only one to three days on average
Based on these results, Medicago will immediately seek registration approval from Health Canada as part of its rolling application
Medicago has initiated the registration and application procedures for plant-derived adjuvant new coronary pneumonia vaccine candidates in the US FDA and UK MHRA
Note: The original text has been deleted